These experimental validations confirm the bioinformatics predictions and substantiate our hypothesis that the downregulation of miR-613 observed in atrial fibrillation patients could contribute to disease progression by relieving repression of SNAI2 and CXCR4 expression. This evidence concerns the gene SNAI2 and atrial fibrillation.